CareDx, Inc is a diagnostics & research business based in the US. CareDx shares (CDNA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $51.32 – a decrease of 2.04% over the previous week. CareDx employs 306 staff and has a trailing 12-month revenue of around $169.4 million.
Since the stock market crash in March caused by coronavirus, CareDx's share price has had significant positive movement.
Its last market close was $51.32, which is 44.95% up on its pre-crash value of $28.25 and 293.56% up on the lowest point reached during the March crash when the shares fell as low as $13.04.
If you had bought $1,000 worth of CareDx shares at the start of February 2020, those shares would have been worth $671.49 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,107.71.
|Latest market close||$51.32|
|52-week range||$13.04 - $79.92|
|50-day moving average||$62.5196|
|200-day moving average||$43.5205|
|Wall St. target price||$68|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.971|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-15)||-58.16%|
|1 month (2020-12-22)||-52.16%|
|3 months (2020-10-22)||-27.33%|
|6 months (2020-07-22)||6.93%|
|1 year (2020-01-22)||65.46%|
|2 years (2019-01-22)||47.23%|
|3 years (2018-01-22)||486.33%|
|5 years (2016-01-22)||599.81%|
|Revenue TTM||$169.4 million|
|Gross profit TTM||$81.6 million|
|Return on assets TTM||-5.34%|
|Return on equity TTM||-10.91%|
|Market capitalisation||$3.8 billion|
TTM: trailing 12 months
There are currently 4.8 million CareDx shares held short by investors – that's known as CareDx's "short interest". This figure is 2.5% up from 4.7 million last month.
There are a few different ways that this level of interest in shorting CareDx shares can be evaluated.
CareDx's "short interest ratio" (SIR) is the quantity of CareDx shares currently shorted divided by the average quantity of CareDx shares traded daily (recently around 569356.63507109). CareDx's SIR currently stands at 8.44. In other words for every 100,000 CareDx shares traded daily on the market, roughly 8440 shares are currently held short.
However CareDx's short interest can also be evaluated against the total number of CareDx shares, or, against the total number of tradable CareDx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CareDx's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 CareDx shares in existence, roughly 100 shares are currently held short) or 0.1105% of the tradable shares (for every 100,000 tradable CareDx shares, roughly 111 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CareDx.
Find out more about how you can short CareDx stock.
We're not expecting CareDx to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, CareDx's shares have ranged in value from as little as $13.04 up to $79.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CareDx's is 0.7969. This would suggest that CareDx's shares are less volatile than average (for this exchange).
CareDx, Inc., a precision medicine company, discovers, develops, and commercializes healthcare solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; and AlloMap Heart, a gene expression solution for heart transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and solid organs. In addition, it offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a solution for use in transplantation diagnostic testing. Further, the company provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI and Waitlist Management solutions. It offers its products directly to customers, as well as through third-party distributors. The company has a license agreement with Illumina, Inc. for the development, commercialization, and distribution of next generation sequencing product line for use in transplantation diagnostic testing; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.